AASLD (2017). Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology, 62:932–954.
Bansal S, Singal AK, McGuire BM and Anand BS. (2015). Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. World J Hepatol, 7(5):806-13.
Bayliss MS, Gandek B, Bungay KM, Sugano D, Hsu MA and Ware JE Jr. (1998). A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res, 7(1):39-55.
Belfer I. (2017). Pain in women. Agri, 29(2):51-54.
Bernstein D, Kleinman L, Barker CM, Revicki DA and Green J. (2002). Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology, 35: 704-708
Bertino G, Ardiri A, Proiti M, Rigano G, Frazzetto E, et al. (2016). Chronic hepatitis C: This and the new era of treatment. World J Hepatol, 8(2):92-106.
Bertino G, Malaguarnera G, Frazzetto E, Sciuto A, et al. (2018). Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions. World J Hepatol, 10(6):448-45.
Bethea ED, Chen Q, Hur C, Chung RT and Chhatwal J. (2018). Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology, 67(3):837-846.
Bullinger M, Alonso J, Apolone G, Leplège A, Sullivan M, et al. (1998). Translating health status questionnaires and evaluating their quality: the IQOLA Project approach. International Quality of Life Assessment. J ClinEpidemiol, 51(11):913-23.
Cabibbo G, Celsa C, Calvaruso V, Petta S, Cacciola I, et al. (2019). Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol, S0168-8278(19)30221-1.
Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, et al. (2017). Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicenter study. Aliment Pharmacol Ther, 46(7):688-695.
Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, et al. (2018). Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology, 155(2):411-421.e4.
Calvaruso V, Cacciola I, Licata A, Madonia S, et al. (2019). Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience. Am J Gastroenterol, 114(8):1275-1282.
Cartabellotta F, Di Marco V, Raimondo G, Craxì A, Bertino G, et al. (2016). The HCV Sicily Network: a web-based model for the management of HCV chronic liver diseases. European Review For Medical And Pharmacological Science, 20 (1 Suppl.): 11-16.
Corsaro LS and Ragusa R. (2018). Oral Direct Acting Agent Clinical Trials for Hepatitis C Virus Infection: An Updated Meta-Analysis. EC Gastroenterology and Digestive System, 5(6): 447-455.
Di Matteo M, Lepper HS and Croghan TW. (2000). Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Archives of Internal Medicine, 160(14):2101–7
Ebrahim S. (1995). Clinical and public health perspectives and applications of health-related quality of life measurement. Social Science and Medicine, 41:1383–94.
European Association for the Study of the Liver. (2018). EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol, 69(2):461-511.
Gold MR, Patrick DL, Torrance GW, Fryback D, Hadorn DC, et al. (1996). Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press.
Horsmans Y. (2006). Interferon-induced depression in chronic hepatitis C. J Antimicrob Chemother, 58:711-3.
Katon W, Lin EHB and Kroenke K. (2007). The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. General Hospital Psychiatry, 29(2):147–55
Keefe B. (2007). Interferon-induced depression in hepatitis C: an update. Curr Psychiatry Rep, 9:255-61.
Kuna L, Jakab J, Smolic R, Wu GY and Smolic M. (2019). HCV Extrahepatic Manifestations. J Clin Transl Hepatol, 7(2):172-182.
Mandorfer M, Payer BA, Scheiner B, et al. (2014). Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. Liver Int, 34(1):69-77.
Maruish ME (Ed.). (2011). User’s Manual for the SF-36v2 Health Survey (3rd ed.), QualityMetric Incorporated, Lincoln, RI (2011)
McHutchison JG, Manns M, Patel K, Poynard T, et al. (2002). Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology, 123: 1061-1069
Peasgood T, Brazier J, Mukuria C and Rowen D. (2014). A conceptual comparison of well-being measures used in the UK. Policy Research Unit in Economic Evaluation of Health and Care Interventions. Universities of Sheffield & York. EEPRU Research Report 026. Policy paper/document 01/09/2014.
Pieretti S, Di Giannuario A, Di Giovannandrea R, Marzoli F, Piccaro G, et al. (2016). Gender differences in pain and its relief. Ann Ist Super Sanita, 52(2):184-9
Polo ML and Laufer N. (2017). Extrahepatic manifestations of HCV: the role of direct acting antivirals. Expert Rev Anti Infect Ther, 15(8):737-746.
Quelhas R and Lopes A. (2009). Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment with Interferon-alpha: a review. J Psychiatr Pract, 15:262-81.
Ragusa R, Bertino G, Bruno A, Frazzetto E, et al. (2018). Evaluation of health status in patients with hepatitis c treated with and without Interferon. Health Qual Life Outcomes, 16(1):17.
Ragusa R, Corsaro LS, Frazzetto E, Bertino E, et al. (2020). Hepatitis C Virus Infection in Children and Pregnant Women: An Updated Review of the Literature on Screening and Treatments. AJP Rep, 10(1): e121-e127.
Scheiner B, Schwabl P, Steiner S, et al. (2016). Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study. Medicine (Baltimore), 95(27): e4061
Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH and Raczek A. (1995). Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care, 33 (Suppl.):AS264-79.
Wei L and Huang YH. (2019). Long-term outcomes in patients with chronic hepatitis C inthe current era of direct-acting antiviral agents. Expert Rev Anti Infect Ther, 17(5):311-325.
World Health Organization. (2014). Constitution of the World Health Organization. 48th ed. Basic documents of the World Health Organization. Geneva.
Younossi Z and Henry L. (2015). Systematic review: patient-reported outcomes in chronic hepatitis C–the impact of liver disease and new treatment regimens. Aliment PharmacolTher, 41:497–520.